Efinopegdutide (MK-6024): A Comprehensive Profile of an Investigational Dual GLP-1/Glucagon Receptor Agonist for Metabolic Liver Disease

I. Introduction to Efinopegdutide (MK-6024)

A. Overview

Efinopegdutide is an investigational biopharmaceutical agent currently undergoing clinical evaluation, primarily for the treatment of metabolic liver diseases such as nonalcoholic steatohepatitis (NASH), a condition increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH).[1] It represents a novel therapeutic approach based on its mechanism as a potent dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).[4] This dual agonism is hypothesized to confer specific advantages in managing the complex pathophysiology of NASH/MASH, potentially offering greater efficacy in reducing liver fat and inflammation compared to therapies targeting only the GLP-1 pathway.[5]

The development trajectory of Efinopegdutide has involved multiple pharmaceutical entities, reflected in its various identifiers throughout its history. This suggests a complex path influenced by shifting strategic priorities and evolving assessments of the drug's therapeutic potential across different indications.[4] The consistent emphasis on its dual GLP-1/Glucagon mechanism, however, underscores this feature as the central scientific rationale driving its current development focus on liver disease.[4]

B. Identification

The compound is internationally recognized by the nonproprietary name Efinopegdutide. Key identifiers used during its development and within scientific databases include: